Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹63 Cr.
Stock P/E
15.4
P/B
1.7
Current Price
₹92
Book Value
₹ 54.8
Face Value
10
52W High
₹136
52W Low
₹ 74.3
Dividend Yield
—

Aristo Bio-Tech Overview

Business

Aristo Bio-Tech and Lifescience Ltd. is an Indian company engaged in the development, manufacturing, and marketing of a range of organic and biological agricultural inputs. Its core business revolves around providing sustainable solutions for agriculture, including bio-pesticides, bio-fertilizers, plant growth regulators (PGRs), and soil conditioners. The company operates on a business model of in-house research and development for new formulations, manufacturing these products, and then distributing them to farmers primarily through a network of dealers and distributors. It generates revenue by selling these agricultural biological products across various crop cycles and farming practices.

Revenue Mix

The company's product portfolio is broadly categorized into:

Bio-Pesticides (e.g., controlling pests naturally)

Bio-Fertilizers (e.g., enhancing soil fertility and nutrient uptake)

Plant Growth Regulators (PGRs) (e.g., improving plant health and yield)

Soil Conditioners (e.g., improving soil structure and water retention)

It also engages in custom synthesis and contract manufacturing services for other agricultural companies.

Specific revenue contributions from each segment are not readily disclosed in the public domain for this company.

Industry

Aristo Bio-Tech operates within India's broader pesticides and agrochemicals sector, specifically targeting the rapidly growing segment of organic and biological agri-inputs. The Indian agrochemical industry is diverse, with large players dominating chemical pesticides and a fragmented but expanding landscape for bio-agri inputs. Aristo Bio-Tech positions itself as a player focused on sustainable and eco-friendly agricultural solutions. As an SME listed on the NSE SME platform, it is a relatively smaller entity compared to large integrated chemical agrochemical companies but aims to gain market share in the niche of biological inputs, driven by increasing farmer awareness and consumer demand for organic produce.

MOAT

While lacking the scale of large agrochemical giants, Aristo Bio-Tech's competitive advantages are likely derived from:

Specialized R&D and Formulations: Expertise in developing effective and stable biological formulations tailored to Indian agricultural conditions and specific crop needs.

Distribution Network: Building and maintaining a dedicated distribution network for its specific product range, which can be crucial for reaching diverse farmer communities.

Quality and Efficacy: A reputation for producing high-quality and effective bio-inputs, which can build farmer loyalty in a segment where product performance is paramount.

These advantages create a niche rather than a broad, impenetrable moat, requiring continuous innovation and market presence.

Growth Drivers

Rising Demand for Organic/Sustainable Farming: Increasing consumer preference for organic produce and growing environmental awareness drives demand for bio-agri inputs.

Government Support: Initiatives and policies promoting sustainable agriculture, reducing chemical pesticide use, and supporting organic farming practices.

Expanding Product Portfolio: Continuous R&D to introduce new and more effective bio-pesticides, bio-fertilizers, and PGRs.

Farmer Awareness: Increasing education and acceptance among farmers regarding the long-term benefits of bio-inputs for soil health, crop quality, and yield.

Market Penetration: Expanding its distribution network and reach into new agricultural regions within India.

Risks

Weather Dependency: The company's performance is intrinsically linked to agricultural output, which is highly dependent on favorable monsoon and weather conditions.

Regulatory Changes: Potential changes in government policies, registration processes, or environmental regulations pertaining to bio-inputs could impact operations.

Intense Competition: Competition from both established chemical agrochemical companies entering the bio-segment and other specialized bio-input manufacturers.

Raw Material Price Volatility: Fluctuations in the cost of biological raw materials can impact profit margins.

Product Efficacy Perception: Bio-inputs sometimes face challenges in farmer adoption due to perceptions of slower action or lower immediate efficacy compared to chemical alternatives.

Limited Scale: As an SME, it may face constraints in large-scale R&D investment, marketing budgets, and distribution reach compared to larger competitors.

Management & Ownership

Aristo Bio-Tech and Lifescience Ltd. is promoted by individuals like Mr. Chetan Singh Chaudhari and Mr. Harshvardhan Singh, who are instrumental in guiding the company's vision and strategy. As is common with many Indian SMEs, the promoters typically hold a significant stake, reflecting a promoter-driven approach to business operations and growth. The management team would likely consist of professionals with expertise in agriculture, biotechnology, manufacturing, and marketing, focused on expanding the company's presence in the sustainable agri-inputs market.

Outlook

Aristo Bio-Tech is strategically positioned in the evolving bio-agri inputs market, benefiting from strong tailwinds such as growing demand for sustainable farming and supportive government policies. Its focus on specialized R&D and a dedicated distribution network could drive market penetration and growth within its niche. However, its relatively smaller scale, intense competition from both domestic and international players, and the inherent risks associated with the agricultural sector (e.g., monsoon variability, pest resistance) present significant challenges. Sustained growth will hinge on the company's ability to innovate effectively, scale up manufacturing and distribution, and continuously demonstrate the efficacy and value of its products to a diverse farmer base while navigating regulatory complexities.

Aristo Bio-Tech Share Price

Live · NSE · Inception: 2005
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Aristo Bio-Tech Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Aristo Bio-Tech Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 202 201 167 166 218 245 318
Other Income 0 0 0 0 0 0 1
Total Income 202 201 167 166 218 245 319
Total Expenditure 195 197 163 161 209 237 309
Operating Profit 7 5 5 5 9 9 10
Interest 2 3 2 2 3 2 2
Depreciation 1 1 1 1 2 2 3
Exceptional Income / Expenses -0 0 0 0 0 0 0
Profit Before Tax 4 1 1 2 5 5 5
Provision for Tax 1 0 0 1 1 2 1
Profit After Tax 3 1 1 1 4 4 4
Adjustments 0 0 0 0 0 0 0
Profit After Adjustments 3 1 1 1 4 4 4
Adjusted Earnings Per Share 5.7 2 2.2 2.9 5.2 5.7 6

Aristo Bio-Tech Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 11 12 13 15 30 34 37
Minority's Interest 0 0 0 0 0 0 0
Borrowings 7 11 12 11 10 10 8
Other Non-Current Liabilities -0 -0 0 0 0 0 0
Total Current Liabilities 72 65 56 51 59 84 96
Total Liabilities 91 88 81 77 100 127 141
Fixed Assets 8 8 12 14 16 22 24
Other Non-Current Assets 2 3 0 0 2 1 1
Total Current Assets 81 77 69 63 83 105 116
Total Assets 91 88 81 77 100 127 141

Aristo Bio-Tech Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 1 0 0 2 1
Cash Flow from Operating Activities 8 1 2 7 -3 8 10
Cash Flow from Investing Activities -2 -2 -2 -3 -4 -7 -5
Cash Flow from Financing Activities -6 1 -1 -3 8 -2 -4
Net Cash Inflow / Outflow -0 0 -0 0 1 -1 0
Closing Cash & Cash Equivalent 0 1 0 0 2 1 1

Aristo Bio-Tech Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 5.66 2.02 2.15 2.87 5.23 5.72 5.97
CEPS(Rs) 6.68 3.06 3.65 5.07 7.49 8.03 9.79
DPS(Rs) 0 0 0 0 0.25 0.4 0.5
Book NAV/Share(Rs) 22.62 24.63 26.79 29.76 44.3 49.37 54.84
Core EBITDA Margin(%) 2.91 1.91 2.22 3.12 3.99 3.44 2.92
EBIT Margin(%) 2.71 1.7 1.94 2.62 3.44 2.93 2.32
Pre Tax Margin(%) 1.75 0.59 0.76 1.19 2.18 2.21 1.72
PAT Margin (%) 1.21 0.43 0.55 0.86 1.64 1.59 1.28
Cash Profit Margin (%) 1.42 0.65 0.93 1.53 2.34 2.23 2.1
ROA(%) 3.12 1.13 1.27 1.81 4.03 3.43 3.03
ROE(%) 25.03 8.54 8.38 10.15 15.82 12.22 11.46
ROCE(%) 24.67 13.84 11.27 11.43 16.11 13.41 12.96
Receivable days 65.74 70.19 75.46 72.63 65.15 75.97 65.21
Inventory Days 51.31 44.41 52.38 61.99 46.19 52.83 50.23
Payable days 124.02 97.68 92.64 91.29 75.14 92.7 91.34
PER(x) 0 0 0 0 10.71 10.91 19.47
Price/Book(x) 0 0 0 0 1.27 1.27 2.12
Dividend Yield(%) 0 0 0 0 0.45 0.64 0.43
EV/Net Sales(x) 0.09 0.12 0.16 0.18 0.27 0.26 0.31
EV/Core EBITDA(x) 2.74 5.35 5.95 5.52 6.51 7.17 10.02
Net Sales Growth(%) 0 -0.22 -16.9 -0.87 31.43 12.53 29.76
EBIT Growth(%) 0 -37.07 -4.62 13.95 72.49 -4.14 2.54
PAT Growth(%) 0 -64.38 6.78 33.29 148.44 9.36 4.3
EPS Growth(%) 0 -64.38 6.78 33.29 82.29 9.36 4.3
Debt/Equity(x) 1.28 1.6 1.66 1.71 0.75 0.62 0.59
Current Ratio(x) 1.12 1.18 1.23 1.23 1.39 1.26 1.21
Quick Ratio(x) 0.66 0.81 0.66 0.75 0.87 0.78 0.72
Interest Cover(x) 2.82 1.54 1.65 1.84 2.72 4.05 3.88
Total Debt/Mcap(x) 0 0 0 0 0.59 0.49 0.28

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +30% +24% +10% —
Operating Profit CAGR +11% +26% +15% —
PAT CAGR 0% +59% +32% —
Share Price CAGR -31% +6% — —
ROE Average +11% +13% +12% +13%
ROCE Average +13% +14% +13% +15%

Aristo Bio-Tech Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 73.42 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 26.58 %
# Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
Promoter 73.3773.3773.3773.3773.4273.4273.42
FII 0000000
DII 0000000
Public 26.6326.6326.6326.6326.5826.5826.58
Others 0000000
Total 100100100100100100100

Aristo Bio-Tech Peer Comparison

Pesticides & Agrochemicals Edit Columns

Aristo Bio-Tech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Aristo Bio-Tech Pros & Cons

Pros

  • Company has delivered good profit growth of 31% CAGR over last 5 years
  • Debtor days have improved from 92.7 to 91.34days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of 13% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp